MedTrace Logo

Comparison of Efficacy of Triple Regimen Based on Clarithromycin VS Metronidazole in Children

NCT04721704 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-01-26

No results posted yet for this study

Summary

All children from 1day to 18years of age, diagnosed with peptic ulcer disease due to H pylori at Pakistan Institute of Medical Sciences, Islamabad, from July 2020 to December 2021 will be included in the study. After informed written consent from parents/ guardians patients' bio data along with history and examination will be recorded on a proforma. They will be allocated into two groups, group A and group B randomly based on treatment regimen offered.

Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI) Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI The history will include presenting symptoms along duration, remission of symptoms after therapy and clinical outcome will also be recorded.

Conditions

  • H Pylori Gastritis

Interventions

DRUG

Clarithromycin+ Amoxicillin + Omeprazole

In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children

DRUG

Metronidazole +Amoxicillin + Omeprazole

Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI

Sponsors & Collaborators

  • Shaheed Zulfiqar Ali Bhutto Medical University

    lead OTHER

Principal Investigators

  • Nadia Waheed · PIMS, SZABMU,ISLAMABAD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-14
Primary Completion
2022-09-14
Completion
2022-09-14

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04721704 on ClinicalTrials.gov